<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Clinical staging and histological grading after surgery have been the "gold standard" for predicting prognosis and planning for adjuvant therapy of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>With the recent development of molecular markers, it has become possible to characterize <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> at the molecular level </plain></SENT>
<SENT sid="2" pm="."><plain>This is important for stage II and III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>, in which clinicopathological features do not accurately predict <z:hpo ids='HP_0001425'>heterogeneity</z:hpo>, e.g., in their <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> response to adjuvant therapy </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, archival samples from 141 patients with stage I, II, III, or IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> treated during 1981-1990 at Turku University Hospital (Finland) were used (as microarray blocks) to analyze MUC2 expression by immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>Altogether, 49.7 % of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were positive for MUC2 </plain></SENT>
<SENT sid="5" pm="."><plain>There was no significant correlation between MUC2 expression and age (P &lt; 0.499), <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> invasion (P &lt; 0.127), <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> staging (P &lt; 0.470), histological grade (P &lt; 0.706), lymph node involvement (P &lt; 0.854), or <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumor metastasis</z:e> (P &lt; 0.586) </plain></SENT>
<SENT sid="6" pm="."><plain>However, loss of MUC2 expression was significantly associated with disease recurrence (P &lt; 0.031), <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> localization (P &lt; 0.048), and with borderline significance with gender (P &lt; 0.085) </plain></SENT>
<SENT sid="7" pm="."><plain>In univariate (Kaplan-Meier) survival analysis, positive MUC2 significantly predicted longer disease-free survival (DFS) and disease-specific survival (DSS) as well </plain></SENT>
<SENT sid="8" pm="."><plain>However, in multivariate (Cox) survival analysis, MUC2 lost its power as an independent predictor of DFS and DSS </plain></SENT>
<SENT sid="9" pm="."><plain>Our results implicate the value of MUC2 expression in predicting disease recurrence and long-term survival in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>